Details for New Drug Application (NDA): 012122
✉ Email this page to a colleague
NDA 012122 describes GLUCAGON, which is a drug marketed by Amphastar Pharms Inc, Lilly, and Fresenius Kabi Usa, and is included in four NDAs. It is available from four suppliers. Additional details are available on the GLUCAGON profile page.
The generic ingredient in GLUCAGON is glucagon hydrochloride. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the glucagon hydrochloride profile page.
The generic ingredient in GLUCAGON is glucagon hydrochloride. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the glucagon hydrochloride profile page.
Summary for 012122
| Tradename: | GLUCAGON |
| Applicant: | Lilly |
| Ingredient: | glucagon hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 10MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
